Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. Spur Therapeutics is a clinical-stage biotech company dedicated to developing next generation gene therapies for people living with chronic, debilitating diseases. Its lead candidate, FLT201, is an AAV gene therapy for Gaucher...
Podden och tillhörande omslagsbild på den här sidan tillhör Labiotech. Innehållet i podden är skapat av Labiotech och inte av, eller tillsammans med, Poddtoppen.
